Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Severe alcoholism may be treated with low doses of ketamine and psychological therapy

Staff Writer
Staff Writer 4 months ago
Updated 2022/01/11 at 12:52 AM
Share
SHARE

For many years, a lack of effective treatment for severe alcoholism have provided a challenge for clinicians. New research, however, suggests that low doses of ketamine, coupled with sessions of psychological therapy, may be sufficient to stave off symptoms of severe alcoholism.

To determine how ketamine could be used to inhibit a relapse of alcoholism, researchers turned to the Ketamine for Reduction of Alcohol Relapse (KARE) trial conducted by the University of Exeter.

The KARE trial is the first of its kind that compares ketamine and psychological therapy. The study was publicized in the American Journal of Psychiatry.

For the study, 96 people with a history of alcoholism were assessed. Among the participants, it was concluded that ketamine combined with psychological therapy resulted in complete soberness for 162 of 180 days upon a six-month follow-up period.

The findings indicate that the component of therapy may increase the chances of preventing relapse.

“Alcoholism can destroy lives, and we urgently need new ways to help people cut down,” according to the journal report.

“We found that controlled, low doses of ketamine combined with psychological therapy can help people stay off alcohol for longer than placebo. This is extremely encouraging, as we normally see three out of every four people returning to heavy drinking within six months of quitting alcohol, so this result represents a great improvement”

Photo: Getty Images

You Might Also Like

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

TAGGED: alcoholism, ketamine
Staff Writer January 10, 2022
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article New link between stress and Crohn’s disease uncovered
Next Article Long-term use of ACE inhibitors for the treatment of high blood pressure may lead to kidney damage

Recommended

Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?